Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes
Sponsor: Novo Nordisk A/S
Summary
The purpose of this clinical study is to find out how the novel insulin NNC0363-1063 and a non-glucose carbohydrate used in food and beverage might interact in participants with type 1 diabetes and if co-administration of these substances is safe and tolerable. All participants will get a fixed dose of NNC0363-1063 and an oral administration of different amounts of the non-glucose carbohydrate in a random order during 4 interaction tests. The participants will be in this clinical study for about 5 to 12 weeks.
Official title: A Multiple Dose Study Investigating Pharmacodynamics and Pharmacokinetics of Subcutaneous NNC0363-1063 in Participants With Type 1 Diabetes
Key Details
Gender
All
Age Range
18 Years - 64 Years
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2025-12-15
Completion Date
2026-05-21
Last Updated
2026-01-02
Healthy Volunteers
No
Conditions
Interventions
NNC0363-1063
NNC0363-1063 will be administered subcutaneously.
Locations (1)
Profil Institut für Stoffwechselforschung GmbH
Neuss, Germany